U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07441889) titled 'HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)' on Feb. 10.
Brief Summary: The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast or prostate cancer. Participants receive 5 weekly doses of CD33 FPBMC by intravenous infusion followed by 4 infusions every other week.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Prostate Cancer
Intervention:
DRUG: HER2 FPBMC
Participants will receive 5 weekly in...